论文部分内容阅读
目的探讨乳腺癌患者手术后采用表柔比星化疗和辅助放疗心电图异常的影响因素。方法选取51例乳腺癌术后采用表柔比星化疗和辅助放疗患者的临床资料进行分析,分析心电图异常与年龄、肿瘤部位、基础疾病、内分泌治疗、含表柔比星累积剂量和放疗方式之间的关系。结果11例患者出现心电图异常,占21.6%;年龄≥50岁、伴有基础疾病、含表柔比星累积剂量≥400 mg和电子线放疗方式患者的心电图异常率显著高于年龄<50岁、未伴有基础疾病、含表柔比星累积剂量<400 mg和调强放疗方式患者,差异均有统计学意义(均P<0.05)。结论乳腺癌术后采用表柔比星化疗后辅助放疗导致的心电图异常与患者年龄、基础疾病、含表柔比星累积剂量和放疗方式有一定关系。
Objective To investigate the influencing factors of electrocardiogram abnormalities after epirubicin chemotherapy and adjuvant radiotherapy in patients with breast cancer after operation. Methods The clinical data of 51 patients with breast cancer who were treated with epirubicin and adjuvant radiotherapy were analyzed. The differences of ECG abnormalities, age, tumor location, underlying diseases, endocrine therapy, cumulative dose of epirubicin and radiotherapy were analyzed Relationship between. Results Electrocardiogram abnormalities occurred in 11 patients, accounting for 21.6%. The abnormal ECG rate of patients aged ≥50 years with underlying diseases, cumulative dose of epirubicin ≥400 mg and electron beam radiation was significantly higher than those of patients <50 years old, Patients without underlying disease, including cumulative dose of epirubicin <400 mg, and intensity modulated radiation therapy had statistically significant differences (all P <0.05). Conclusions Electrocardiogram abnormalities caused by adjuvant radiotherapy after epirubicin chemotherapy after breast cancer are related to patients’ age, underlying diseases, cumulative dose of epirubicin and radiotherapy.